Floatz logo

azd6244

Histiocytic Sarcoma

National Cancer Institute (NCI)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Histiocytic Sarcoma cohort.

Asset / SponsorPhaseRating
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493
National Cancer Institute (NCI)
Phase 2CCC
Palbociclib
National Cancer Institute (NCI)
Phase 2CCC
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2CCC
Ulixertinib
National Cancer Institute (NCI)
Phase 2CCC
Pembrolizumab
Dana-Farber Cancer Institute
Phase 2CCC

View all 14 →

Same molecule, other indications

azd6244 is also rated in:

Stage IV Pancreatic CancerDormant
BB
Indicative ·
70 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
67 / 100
View asset →
Colon NeoplasmsDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →